Clinical trial
Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants With Type 2 Diabetes
NCT05478252 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 3, 2022
- Completion date
- September 18, 2023
- Enrollment
- 388 (actual)
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.